NOVO NORDISK A/S-B (NOV.DE) Fundamental Analysis & Valuation

FRA:NOV • DK0062498333

Current stock price

31.775 EUR
-0.08 (-0.24%)
Last:

This NOV.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. NOV.DE Profitability Analysis

1.1 Basic Checks

  • In the past year NOV was profitable.
  • In the past year NOV had a positive cash flow from operations.
  • In the past 5 years NOV has always been profitable.
  • In the past 5 years NOV always reported a positive cash flow from operatings.
NOV.DE Yearly Net Income VS EBIT VS OCF VS FCFNOV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

1.2 Ratios

  • The Return On Assets of NOV (18.87%) is better than 98.04% of its industry peers.
  • The Return On Equity of NOV (52.79%) is better than 92.16% of its industry peers.
  • NOV has a Return On Invested Capital of 30.79%. This is amongst the best in the industry. NOV outperforms 94.12% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for NOV is significantly above the industry average of 14.61%.
  • The 3 year average ROIC (43.61%) for NOV is well above the current ROIC(30.79%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 18.87%
ROE 52.79%
ROIC 30.79%
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
NOV.DE Yearly ROA, ROE, ROICNOV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • With an excellent Profit Margin value of 33.14%, NOV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Profit Margin of NOV has remained more or less at the same level.
  • The Operating Margin of NOV (41.30%) is better than 94.12% of its industry peers.
  • NOV's Operating Margin has been stable in the last couple of years.
  • NOV has a better Gross Margin (80.98%) than 84.31% of its industry peers.
  • In the last couple of years the Gross Margin of NOV has remained more or less at the same level.
Industry RankSector Rank
OM 41.3%
PM (TTM) 33.14%
GM 80.98%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
NOV.DE Yearly Profit, Operating, Gross MarginsNOV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

3

2. NOV.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NOV is creating value.
  • NOV has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NOV has been increased compared to 5 years ago.
  • The debt/assets ratio for NOV is higher compared to a year ago.
NOV.DE Yearly Shares OutstandingNOV.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B
NOV.DE Yearly Total Debt VS Total AssetsNOV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100B 200B 300B 400B 500B

2.2 Solvency

  • An Altman-Z score of 3.57 indicates that NOV is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.57, NOV is in line with its industry, outperforming 54.90% of the companies in the same industry.
  • NOV has a debt to FCF ratio of 4.52. This is a neutral value as NOV would need 4.52 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.52, NOV is in line with its industry, outperforming 56.86% of the companies in the same industry.
  • NOV has a Debt/Equity ratio of 0.61. This is a neutral value indicating NOV is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.61, NOV perfoms like the industry average, outperforming 49.02% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.52
Altman-Z 3.57
ROIC/WACC4.57
WACC6.74%
NOV.DE Yearly LT Debt VS Equity VS FCFNOV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.3 Liquidity

  • A Current Ratio of 0.80 indicates that NOV may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.80, NOV is doing worse than 86.27% of the companies in the same industry.
  • NOV has a Quick Ratio of 0.80. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.57, NOV is doing worse than 86.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.57
NOV.DE Yearly Current Assets VS Current LiabilitesNOV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B 200B

4

3. NOV.DE Growth Analysis

3.1 Past

  • NOV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.77%.
  • Measured over the past years, NOV shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.66% on average per year.
  • The Revenue has been growing slightly by 6.43% in the past year.
  • NOV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.48% yearly.
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%

3.2 Future

  • Based on estimates for the next years, NOV will show a small growth in Earnings Per Share. The EPS will grow by 5.80% on average per year.
  • The Revenue is expected to grow by 4.07% on average over the next years.
EPS Next Y-3.96%
EPS Next 2Y-2.8%
EPS Next 3Y1.16%
EPS Next 5Y5.8%
Revenue Next Year-4.65%
Revenue Next 2Y-0.75%
Revenue Next 3Y1.62%
Revenue Next 5Y4.07%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NOV.DE Yearly Revenue VS EstimatesNOV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100B 200B 300B
NOV.DE Yearly EPS VS EstimatesNOV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

6

4. NOV.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 10.32, the valuation of NOV can be described as very reasonable.
  • NOV's Price/Earnings ratio is rather cheap when compared to the industry. NOV is cheaper than 82.35% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of NOV to the average of the S&P500 Index (25.61), we can say NOV is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 10.73, the valuation of NOV can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NOV indicates a rather cheap valuation: NOV is cheaper than 80.39% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.79. NOV is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 10.32
Fwd PE 10.73
NOV.DE Price Earnings VS Forward Price EarningsNOV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NOV is valued cheaply inside the industry as 82.35% of the companies are valued more expensively.
  • NOV's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 36.4
EV/EBITDA 7.76
NOV.DE Per share dataNOV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The excellent profitability rating of NOV may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.5
EPS Next 2Y-2.8%
EPS Next 3Y1.16%

7

5. NOV.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 4.92%, NOV is a good candidate for dividend investing.
  • In the last 3 months the price of NOV has falen by -28.46%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 1.90, NOV pays a better dividend. On top of this NOV pays more dividend than 86.27% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, NOV pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.92%

5.2 History

  • On average, the dividend of NOV grows each year by 19.05%, which is quite nice.
Dividend Growth(5Y)19.05%
Div Incr Years0
Div Non Decr Years0
NOV.DE Yearly Dividends per shareNOV.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 2 4 6 8 10

5.3 Sustainability

  • NOV pays out 50.53% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The dividend of NOV is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP50.53%
EPS Next 2Y-2.8%
EPS Next 3Y1.16%
NOV.DE Yearly Income VS Free CF VS DividendNOV.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B
NOV.DE Dividend Payout.NOV.DE Dividend Payout, showing the Payout Ratio.NOV.DE Dividend Payout.PayoutRetained Earnings

NOV.DE Fundamentals: All Metrics, Ratios and Statistics

NOVO NORDISK A/S-B

FRA:NOV (3/25/2026, 7:00:00 PM)

31.775

-0.08 (-0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-03
Earnings (Next)05-06
Inst Owners32.22%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap141.24B
Revenue(TTM)309.06B
Net Income(TTM)102.43B
Analysts69.41
Price Target49.38 (55.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.92%
Yearly Dividend1.56
Dividend Growth(5Y)19.05%
DP50.53%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.82%
Min EPS beat(2)-7.04%
Max EPS beat(2)1.39%
EPS beat(4)2
Avg EPS beat(4)-0.71%
Min EPS beat(4)-7.04%
Max EPS beat(4)3.94%
EPS beat(8)5
Avg EPS beat(8)1.01%
EPS beat(12)8
Avg EPS beat(12)1.47%
EPS beat(16)11
Avg EPS beat(16)1.68%
Revenue beat(2)1
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)1.07%
Revenue beat(4)1
Avg Revenue beat(4)-0.92%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)1.07%
Revenue beat(8)3
Avg Revenue beat(8)0.15%
Revenue beat(12)6
Avg Revenue beat(12)0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.84%
PT rev (1m)-8.63%
PT rev (3m)-11.78%
EPS NQ rev (1m)12.35%
EPS NQ rev (3m)0.79%
EPS NY rev (1m)-2.9%
EPS NY rev (3m)-7.38%
Revenue NQ rev (1m)1.33%
Revenue NQ rev (3m)-50.96%
Revenue NY rev (1m)-0.77%
Revenue NY rev (3m)-6.85%
Valuation
Industry RankSector Rank
PE 10.32
Fwd PE 10.73
P/S 3.41
P/FCF 36.4
P/OCF 8.86
P/B 5.44
P/tB 16.49
EV/EBITDA 7.76
EPS(TTM)3.08
EY9.69%
EPS(NY)2.96
Fwd EY9.32%
FCF(TTM)0.87
FCFY2.75%
OCF(TTM)3.59
OCFY11.29%
SpS9.31
BVpS5.84
TBVpS1.93
PEG (NY)N/A
PEG (5Y)0.5
Graham Number20.12
Profitability
Industry RankSector Rank
ROA 18.87%
ROE 52.79%
ROCE 39.01%
ROIC 30.79%
ROICexc 33.56%
ROICexgc 59.2%
OM 41.3%
PM (TTM) 33.14%
GM 80.98%
FCFM 9.38%
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
ROICexc(3y)50.94%
ROICexc(5y)53.03%
ROICexgc(3y)100.46%
ROICexgc(5y)105.49%
ROCE(3y)55.75%
ROCE(5y)58.53%
ROICexgc growth 3Y-22.89%
ROICexgc growth 5Y-7.78%
ROICexc growth 3Y-18.13%
ROICexc growth 5Y-11.63%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
F-Score5
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.52
Debt/EBITDA 0.79
Cap/Depr 409.94%
Cap/Sales 29.16%
Interest Coverage 37.34
Cash Conversion 79.59%
Profit Quality 28.3%
Current Ratio 0.8
Quick Ratio 0.57
Altman-Z 3.57
F-Score5
WACC6.74%
ROIC/WACC4.57
Cap/Depr(3y)363.9%
Cap/Depr(5y)282.93%
Cap/Sales(3y)21.19%
Cap/Sales(5y)15.43%
Profit Quality(3y)60.31%
Profit Quality(5y)79.23%
High Growth Momentum
Growth
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
EPS Next Y-3.96%
EPS Next 2Y-2.8%
EPS Next 3Y1.16%
EPS Next 5Y5.8%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%
Revenue Next Year-4.65%
Revenue Next 2Y-0.75%
Revenue Next 3Y1.62%
Revenue Next 5Y4.07%
EBIT growth 1Y-4.76%
EBIT growth 3Y19.04%
EBIT growth 5Y18.51%
EBIT Next Year8.51%
EBIT Next 3Y5.92%
EBIT Next 5Y7.75%
FCF growth 1Y-58.38%
FCF growth 3Y-23.26%
FCF growth 5Y-0.6%
OCF growth 1Y-1.54%
OCF growth 3Y14.72%
OCF growth 5Y18.05%

NOVO NORDISK A/S-B / NOV.DE Fundamental Analysis FAQ

What is the fundamental rating for NOV stock?

ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.


Can you provide the valuation status for NOVO NORDISK A/S-B?

ChartMill assigns a valuation rating of 6 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.


What is the profitability of NOV stock?

NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.


Can you provide the expected EPS growth for NOV stock?

The Earnings per Share (EPS) of NOVO NORDISK A/S-B (NOV.DE) is expected to decline by -3.96% in the next year.


Is the dividend of NOVO NORDISK A/S-B sustainable?

The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 7 / 10 and the dividend payout ratio is 50.53%.